ADX71743 is a potent positive allosteric modulator (PAM) of the metabotropic glutamate receptor 7 (mGlu7), developed by Addex Therapeutics to treat neurological and psychiatric conditions. By enhancing mGlu7 activity, the compound aims to regulate glutamate neurotransmission to mitigate visceral pain, fear memory, and sleep disorders.
The Role of mGlu7 in Glutamate Regulation
Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system. However, excessive glutamate activity can lead to excitotoxicity and the dysfunction of neural circuits. According to research published in Nature and various pharmacological reviews, metabotropic glutamate receptors (mGluRs) act as “dimmer switches” that modulate this activity.
The mGlu7 receptor is primarily located presynaptically. When activated, it inhibits the release of glutamate from the presynaptic terminal. ADX71743 functions as a positive allosteric modulator, meaning it doesn’t activate the receptor on its own but enhances the receptor’s response to its natural ligand. This mechanism effectively reduces the over-firing of neurons without completely blocking signaling, which often reduces the side-effect profile compared to direct antagonists.
Therapeutic Applications of ADX71743
Addex Therapeutics has positioned ADX71743 as a candidate for several high-need medical areas based on the receptor’s distribution in the brain and spinal cord.
- Visceral Pain: By modulating glutamate release in the spinal cord and brainstem, mGlu7 PAMs can dampen the transmission of pain signals from internal organs.
- Fear Memory and Anxiety: mGlu7 receptors are expressed in the amygdala. Enhancing these receptors can disrupt the consolidation or expression of fear-based memories, offering a potential path for treating PTSD.
- Sleep Regulation: Research indicates that mGlu7 modulation influences the transition between wakefulness and sleep, potentially addressing insomnia or other circadian rhythm disruptions.
Comparative Mechanism: mGlu7 vs. Traditional GABAergics
Many current treatments for anxiety and sleep rely on GABAergic modulation (such as benzodiazepines). While effective, these often cause sedation and dependency. ADX71743 targets the glutamatergic system instead. The following table illustrates the functional difference in approach:
| Feature | GABAergic Modulators (e.g., Benzodiazepines) | mGlu7 PAMs (e.g., ADX71743) |
|---|---|---|
| Primary Target | Inhibitory GABA receptors | Excitatory Glutamate receptors |
| Action | Increases overall inhibition | Decreases excessive excitation |
| Common Side Effects | Sedation, cognitive impairment | Lower risk of global sedation |
Development Status and Clinical Outlook
ADX71743 was discovered by Addex Therapeutics as part of a broader program to map the “mGlu” family of receptors. The company’s strategy focuses on high selectivity; because mGlu7 shares structural similarities with mGlu4, a drug must be highly selective to avoid off-target effects. According to Addex’s corporate disclosures, ADX71743 demonstrates the high potency and selectivity required for further development.
The transition from preclinical models to human trials remains the critical hurdle. The efficacy of ADX71743 in animal models for visceral pain and fear extinction provides the groundwork for establishing safety and dosage in human cohorts.
Frequently Asked Questions
What is a Positive Allosteric Modulator (PAM)?
A PAM is a molecule that binds to a receptor at a site different from where the primary hormone or neurotransmitter binds. It changes the shape of the receptor so that the primary neurotransmitter binds more effectively, increasing the receptor’s activity.
Why target the mGlu7 receptor specifically?
mGlu7 is strategically located to control the “output” of glutamate. By targeting this specific receptor, researchers can reduce the symptoms of hyper-excitability (like chronic pain or panic) without shutting down the brain’s ability to process basic information.
Is ADX71743 available for prescription?
No. ADX71743 is currently an investigational compound and is not approved by the FDA or EMA for general clinical use.
Worth a look